Stem Cells and Cancer news

<p>Clara Campàs, founding partner of Asabys Partners, Salvador Aznar-Benitah and Valerie Vanhooren, founders of Ona Therapeutics, and Sergio Pérez, director of Sabadell Venture Capital</p>
21 May 2019

Ona Therapeutics, a spin-off from IRB Barcelona and ICREA, has been founded by researchers Salvador Aznar-Benitah and Valerie Vanhooren after receiving investment from Sabadell Asabys.

Based at the Barcelona Science Park, the company focuses on the development of a new drug for the treatment of metastatic cancer.

The Sabadell Asabys Fund, which belongs to Asabys Partners, has invested € 1.5M into the company in order to start a venture round that could reach € 20M.

<p>Press conference at IRB Barcelona, presenting the #MetastasisChallenge</p>
19 Mar 2019

Catalunya Ràdio, El Punt Avui, Expansión Catalunya, Europa Press, EFE, among other media, have published an article about the launch of the #MetastasisChallenge campaign. Through this initiative, the Institute for Research in Biomedicine (IRB Barcelona) calls society to action to support research into metastasis—the main cause of death from cancer—by raising €5 M over the next four years.

Link to El Punt Avui

Link to...

<p>Press conference at IRB Barcelona, presenting the #MetastasisChallenge</p>
19 Mar 2019

Through the campaign called #MetastasisChallenge, the centre aims to raise €5 M over the next four years.

Metastasis is responsible for 90% of deaths from cancer, and this campaign aims to rally social support for research in order to speed up discoveries.

<p>Salvador Aznar Benitah leads the Stem Cells and Cancer laboratory at IRB Barcelona</p>
14 Mar 2019

Radio Nacional de España has interviewed Salvador Aznar Benitah, head of the Stem Cells and Cancer lab at IRB Barcelona, about the campaign called #MetastasisChallenge. This initiative seeks to raise € 5 M over four years, funding expected to allow the centre to speed up cancer research by recruiting talent, purchasing new technology and equiping new laboratories, such as a metastasis research unit.

 

<p>Image: Ok Diario</p>
25 Feb 2019

Ok diario and Noticiero Universal have published an article about the research led by IRB Barcelona and CNAG-CRG that confirms that the loss of cellular identity is one of the causes of aging. The paper reports that that, during aging, fibroblasts acquire many characteristics of adipocytes.

Link a Ok diario

Link a Noticiero Universal

 

<p>Gloria Pascual, Research Associate at IRB Barcelona. Picture: Fundación Pfizer</p>
19 Feb 2019

The Pfizer Foundation has awarded the IRB Barcelona scientist a prize within the “Basic Research” category.

Gloria Pascual, a member of the Stem Cells and Cancer lab, will receive €10,000 to continue her research

<p>Biennal Ciutat i Ciència</p>
16 Jan 2019

From 7 to 11 February, the general public will have the opportunity to participate in activities related to ageing, nanoscience and climate change, among others.

IRB Barcelona will be taking part in the Biennal event through three initiatives that target the public.

<p>Quo magazine cover</p>
31 Dec 2018

Quo magazine has published a report on the aesthetic treatments that people use to stay young. They mention, for example, Botox, red light masks, breast prostheses, among others. In the article, they include the statements of experts in the field of health and research and also mention the study performed by IRB Barcelona and CNAG-CRG on the aging of the skin caused by the loss of identity and function of the main cells of the dermis.

 

<p>A invasive front of highly aggressive tumour cells (in green). Confocal microscopy image. Alexandra Avgustinova, IRB Barcelona.</p>
28 Dec 2018

The web Hidden Nature has published an article about the 10 investigations that they considered to be the most important ones published in 2018. One of them refers to epigenetic therapies and mentions research research that supports and rejects them. In this regard, they mention the study led by Salvador Aznar Benitah at IRB Barcelona and published in Nature Cell Biology. The study in question concludes that care must be taken with drugs that inhibit epigenetic factors as they could cause the appearance of aggressive tumours.

Link to Hidden Nature

<p>A invasive front of highly aggressive tumour cells (in green). Confocal microscopy image. Alexandra Avgustinova, IRB Barcelona.</p>
20 Dec 2018

The journal Biocentury Innovations has published an article on the study led by IRB Barcelona researchers Salvador Aznar Benitah and Fran Supek and first-authored by postdoctoral researcher Alexandra Avgustinova. The study has shown that increasing chromatin accessibility in cancer promotes tumour aggressiveness and does not reduce tumour mutation burden, as previously believed. The article refers to one of the main conclusions of the study, namely the need to evaluate the long-term effects of chromatin modifiers in tumour models before taking them into the clinic.